XERS’ XP-8121 targets 2030 launch, $1—3B peak sales
XP-8121 is a once-weekly subcutaneous levothyroxine aimed at 3—5 million hypothyroid patients not controlled on oral therapy, with launch targeted for 2030 and peak sales potential of $1—3 billion.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.